| PNH Phenotypes and Their Genesis |
|
British Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| PNH and complement gene variants |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
|
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia |
|
Immunotherapy |
Aplastic Anemia |
| Pitfalls in Assessing Response to Treatment in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
